AstraZeneca Lung-Cancer Drug Shows Survival Benefit

By Matt Grossman

AstraZeneca PLC said Friday its Imfinzi drug shows a clinically meaningful benefit in overall survival and progression-free survival at five years for patients with unresectable stage-three non-small-cell lung cancer who hadn't progressed following concurrent chemoradiation therapy.

Results from a Phase 3 trial showed an estimated five-year overall survival rate of 42.9% for patients treated with Imfinzi, compared with those who received a placebo after chemoradiation therapy, AstraZeneca said. Median overall survival was 47.5 months for Imfinzi patients, versus 29.1 months for placebo patients.

"Historically, only 15% to 30% of these patients survived five years but these results show that with up to one year of treatment with Imfinzi, an estimated 43% of patients are still alive at five years," Dr. David Spigel, an investigator in the Phase 3 trial, said.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

June 04, 2021 07:50 ET (11:50 GMT)

AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024